Durable response to afatinib rechallenge in a long‐term survivor of non‐small cell lung cancer harboring EGFR L858R and L747V mutations

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors are standard therapeutic agents for non‐small cell lung cancer (NSCLC) patients with major EGFR mutations such as exon 19 deletions and a L858R mutation, whereas treatment strategies for cases with uncommon EGFR mutations remain to b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanbe, Mio, Sunaga, Noriaki, Hara, Kenichiro, Sawada, Hiiru, Wakamatsu, Ikuo, Hara, Kentaro, Muto, Sohei, Sawada, Yuri, Masubuchi, Hiroaki, Sato, Mari, Miura, Yosuke, Tsurumaki, Hiroaki, Yatomi, Masakiyo, Sakurai, Reiko, Koga, Yasuhiko, Ohtaki, Yoichi, Nagashima, Toshiteru, Okano, Naoko, Kubo, Nobuteru, Maeno, Toshitaka, Hisada, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663673/
https://www.ncbi.nlm.nih.gov/pubmed/36193787
http://dx.doi.org/10.1111/1759-7714.14678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663673/
https://www.ncbi.nlm.nih.gov/pubmed/36193787
http://dx.doi.org/10.1111/1759-7714.14678

Ejemplares similares